NEW YORK, December 13, 2016 /PRNewswire/ --
Companies in the Biotech industry primarily use living organisms or molecular and cellular techniques to provide chemicals, food, and services that meet human needs. The segment excludes firms that are primarily involved in developing small-molecule pharmaceuticals, performing contract research, or manufacturing biological equipment. Pre-market, Stock-Callers.com reevaluates the most recent performances of CorMedix Inc. (NYSE MKT: CRMD), Trevena Inc. (NASDAQ: TRVN), Regulus Therapeutics Inc. (NASDAQ: RGLS), and ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC). Learn more about these stocks by downloading their free report at:
New Jersey-based CorMedix Inc.'s stock finished Monday's session 4.60% lower at $1.66 with a total trading volume of 168,322 shares. The Company's shares are trading below their 50-day moving average by 22.15%. Shares of the Company, which intends to in-license, develop, and commercialize prophylactic and therapeutic for the prevention and treatment of infectious and inflammatory diseases, have a Relative Strength Index (RSI) of 34.92.
On November 10th, 2016, CorMedix reported a net loss of $9.1 million, or $0.23 per share, for Q3 2016 compared to a net loss of $4.7, or $0.14 per share, for Q3 2015; an increase of $4.4 million. The Company had $26.7 million in cash and short-term investments as of September 30th, 2016, compared to $28.6 million as of June 30th, 2016. For Q3 2016, the Company used $6.5 million to fund operations, primarily focused on conducting its Neutrolin Phase 3 program and related G&A activities. The free research report on CRMD is available at:
Shares in Pennsylvania-based Trevena Inc. ended at $5.65, down 1.91% from the last trading session. The stockrecorded a trading volume of 309,591 shares. The Company's shares have gained 2.73% in the last one month. The stock is trading 1.22% below its 50-day moving average. Moreover, shares of Trevena, which discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors, have an RSI of 48.99.
On November 03rd 2016, Trevena reported that net loss attributed to common stockholders for Q3 2016 was $29.9 million, or $0.57 per share, compared to $10.6 million, or $0.24 per share for Q3 2015. The company's Research and Development expenses were $25.5 million in Q3 2016 compared to $9.7 million for the Q3 2015, with the increase primarily due to expenses associated with the oliceridine Phase 3 program. The Company expects that R&D expenses will be higher in Q4 2016 compared to Q3 2016 before decreasing in 2017 as ongoing Phase 3 trials are completed. Cash, cash equivalents, and marketable securities totaled $119.6 million as of September 30th, 2016, which Trevena continues to expect will be sufficient to fund its operations into 2018.The complimentary report on TRVN can be downloaded at:
California headquartered Regulus Therapeutics Inc.'s stock ended yesterday's session 4.00% lower at $2.40. A total volume of 510,318 shares was traded, which was above their three months average volume of 438,320 shares. The Company's shares are trading 14.44% below their 50-day moving average. Additionally, shares of Regulus Therapeutics, which focuses on the discovery and development of drugs that target RNAs to treat a range of diseases in the US, have an RSI of 42.37.
On December 06th, 2016, Regulus Therapeutics announced two new drug development candidates at its R&D day, held in New York. The first candidate, RGLS5040, is an anti-miR targeting microRNA-27 (miR-27) for the treatment of cholestatic diseases. The second candidate, RGLS4326, is an anti-miR targeting microRNA-17 (miR-17) for the treatment of autosomal dominant polycystic kidney disease.
On December 07th, 2016, research firm Chardan Capital Markets reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $12 a share to $5 a share.Visit us today and download our complete research report on RGLS for free at:
At the close on Monday, shares in Calabasas, California-based ImmunoCellular Therapeutics Ltd recorded a trading volume of 64,156 shares. The stock finished 7.39% lower at $2.38. The Company's shares have surged 2418.52% in the last one month, 1900.00% over the previous three months, and 569.86% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 172.39% and 513.83%, respectively. Furthermore, shares of ImmunoCellular Therapeutics, which develops immune-based therapies for the treatment of brain and ovarian cancers, have an RSI of 61.46.
On November 21st 2016, ImmunoCellular Therapeutics announced the presentation of updated immune monitoring data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma. ICT-107 is currently being tested in a phase 3 registration trial in patients with newly diagnosed glioblastoma. The ICT-107 phase 2 trial was a randomized, double-blind, placebo-controlled phase 2 study of the safety and efficacy of ICT-107 in patients with newly diagnosed glioblastoma following resection and chemoradiation. Get free access to your technical report on IMUCat:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA